Related Experiment Videos
The endocannabinoid system and Huntington's disease.
I Lastres-Becker1, R De Miguel, J J Fernández-Ruiz
1Departamento de Bioquímica y Biología Molecular III, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain. ilbecker@med.ucm.es
Current Drug Targets. CNS and Neurological Disorders
|October 8, 2003
Summary
Cannabinoids show therapeutic potential for Huntington's disease (HD) by acting on cannabinoid CB(1) receptors. Research suggests the endocannabinoid system is hypofunctional in HD, and cannabinoids may offer symptomatic relief and disease-modifying benefits.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG expansion mutation in the huntingtin gene.
- Clinical symptoms include psychiatric abnormalities, choreiform movements, and dementia, with no current cure.
- The basal ganglia circuitry, affected by striatal atrophy in HD, is a key area of research.
Purpose of the Study:
- To review the biochemical, pharmacological, and therapeutic evidence for cannabinoids in Huntington's disease.
- To explore the role of the endocannabinoid system in HD pathogenesis and potential treatment strategies.
Main Methods:
- Review of recent studies on cannabinoids and Huntington's disease.
- Characterization of cannabinoid CB(1) receptors and their endogenous ligands in animal models of HD.
- Analysis of the endocannabinoid system's function in the context of HD.
Main Results:
- The endocannabinoid system appears hypofunctional in Huntington's disease, potentially linked to early hyperkinetic symptoms.
- Loss of cannabinoid CB(1) receptors may contribute to HD pathogenesis.
- Cannabinoid-related compounds possess known protective properties.
Conclusions:
- Cannabinoids may offer symptomatic relief for Huntington's disease by modulating CB(1) receptors in the basal ganglia.
- Cannabinoids hold potential for delaying or arresting HD progression due to their neuroprotective effects.
- Further research into cannabinoids could lead to novel therapeutic interventions for Huntington's disease.